SHARP Hypofractionated Stereotactic Radiotherapy is Well Tolerated in Prostate Cancer : Toxicity and Quality of Life Assessment

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2016 May 26

PMID 27221312

Citations 9

Authors

Monika Rucinska

Anna Kieszkowska-Grudny

Sergiusz Nawrocki

Affiliations

Soon will be listed here.

Abstract

Background: Quality of life (QoL) is one of the most significant issues in prostate cancer treatment decisions. This study aimed to investigate the toxicity of hypofractionated stereotactic radiotherapy (SBRT) and QoL after treatment in localized prostate cancer patients.

Materials And Methods: A prospective single-center clinical study was performed in low- and intermediate-risk prostate cancer patients. Patients received 33.5 Gy in 5 fractions (SHARP regimen). Acute and late toxicity was assessed according to RTOG/EORTC score. Patients filled out EORTC QLQ-C30 and prostate cancer-specific QLQ-PR25 questionnaires.

Results: The analysis included 68 prostate cancer patients (55-83 years, median 73) with clinical stage T1c-T2cN0M0, median combined Gleason score of 6 (3-8), and median prostate-specific antigen (PSA) level of 10 ng/mL (4-20 ng/mL). Neoadjuvant androgen deprivation therapy was given to 52 patients (76.5 %), and stopped in 31 patients (45.5 %) after 6 months; in 21 patients (31 %) after 2-3 years. Average and median follow-up was 24 months (18-45). Median nadir PSA level was 0.03 ng/mL for all patients and 0.6 ng/mL for patients without hormone treatment. No patients had PSA failure. There were no acute grade IV toxicities. One patient (1.5 %) developed grade III and 24 patients (35.3 %) grade II acute bladder toxicity. No one developed grade III and 7 patients (10.3 %) grade II acute rectal toxicity. No grade III or IV late gastrointestinal or genitourinary toxicities were reported. Grade II late urinary symptoms were observed in 8 patients (11.8 %) and gastrointestinal symptoms in 3 patients (4.4 %). Global health status/QoL was good and improved during the observational period.

Conclusion: SBRT for prostate cancer patients is a well-tolerated treatment in terms of toxicity and QoL, has no negative impact on functioning and everyday life, with the important benefit of a short treatment period. However, long-term follow-up data are needed.

Citing Articles

Volumetric modulated arc therapy (VMAT): a review of clinical outcomes-what is the clinical evidence for the most effective implementation?.

Hunte S, Clark C, Zyuzikov N, Nisbet A Br J Radiol. 2022; 95(1136):20201289.

PMID: 35616646 PMC: 10162061. DOI: 10.1259/bjr.20201289.

Stereotactic Radiation Therapy versus Brachytherapy: Relative Strengths of Two Highly Efficient Options for the Treatment of Localized Prostate Cancer.

Kissel M, Crehange G, Graff P Cancers (Basel). 2022; 14(9).

PMID: 35565355 PMC: 9105931. DOI: 10.3390/cancers14092226.

Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.

Royce T, Mavroidis P, Wang K, Falchook A, Sheets N, Fuller D Int J Radiat Oncol Biol Phys. 2020; 110(1):227-236.

PMID: 32900561 PMC: 9445430. DOI: 10.1016/j.ijrobp.2020.08.014.

Stereotactic body radiation therapy for prostate cancer: systematic review and meta-analysis of prospective trials.

Cushman T, Verma V, Khairnar R, Levy J, Simone 2nd C, Mishra M Oncotarget. 2019; 10(54):5660-5668.

PMID: 31608141 PMC: 6771455. DOI: 10.18632/oncotarget.27177.

Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?.

Roy S, Morgan S Curr Urol Rep. 2019; 20(9):53.

PMID: 31359187 DOI: 10.1007/s11934-019-0918-0.

References

Kim Y, Cho K, Pyo H, Lee K, Moon S, Kim T . Radical prostatectomy versus external beam radiotherapy for localized prostate cancer: Comparison of treatment outcomes. Strahlenther Onkol. 2014; 191(4):321-9. DOI: 10.1007/s00066-014-0765-3. View

Sher D, Parikh R, Mays-Jackson S, Punglia R . Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. Am J Clin Oncol. 2013; 37(3):215-21. DOI: 10.1097/COC.0b013e31827a7d2a. View

Zelefsky M, Chan H, Hunt M, Yamada Y, Shippy A, Amols H . Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006; 176(4 Pt 1):1415-9. DOI: 10.1016/j.juro.2006.06.002. View

Huttenrauch P, Witt M, Wolff D, Bosold S, Engenhart-Cabillic R, Sparenberg J . Target volume coverage and dose to organs at risk in prostate cancer patients. Dose calculation on daily cone-beam CT data sets. Strahlenther Onkol. 2014; 190(3):310-6. DOI: 10.1007/s00066-013-0483-2. View

Madsen B, Hsi R, Pham H, Fowler J, Esagui L, Corman J . Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007; 67(4):1099-105. DOI: 10.1016/j.ijrobp.2006.10.050. View

LLOYD-DAVIES R, Collins C, Swan A . Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). Urology. 1990; 36(2):107-11. DOI: 10.1016/0090-4295(90)80207-4. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

Singh J, Greer P, White M, Parker J, Patterson J, Tang C . Treatment-related morbidity in prostate cancer: a comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2012; 85(4):1018-23. DOI: 10.1016/j.ijrobp.2012.07.2376. View

Panje C, Dal Pra A, Zilli T, Zwahlen D, Papachristofilou A, Herrera F . Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice. Strahlenther Onkol. 2015; 191(10):778-86. DOI: 10.1007/s00066-015-0849-8. View

10.

Duchesne G, Peters L . What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1999; 44(4):747-8. DOI: 10.1016/s0360-3016(99)00024-3. View

11.

Zelefsky M, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X . Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 84(1):125-9. DOI: 10.1016/j.ijrobp.2011.11.047. View

12.

Hodapp N . [The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)]. Strahlenther Onkol. 2012; 188(1):97-9. DOI: 10.1007/s00066-011-0015-x. View

13.

Abramowitz M, Li T, Buyyounouski M, Ross E, Uzzo R, Pollack A . The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2007; 112(1):55-60. DOI: 10.1002/cncr.23139. View

14.

Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M . Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 1999; 44(4):921-9. DOI: 10.1016/s0360-3016(98)00502-1. View

15.

Michalski J, Gay H, Jackson A, Tucker S, Deasy J . Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010; 76(3 Suppl):S123-9. PMC: 3319467. DOI: 10.1016/j.ijrobp.2009.03.078. View

16.

Bauman G, Rumble R, Chen J, Loblaw A, Warde P . Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol (R Coll Radiol). 2012; 24(7):461-73. DOI: 10.1016/j.clon.2012.05.002. View

17.

Zaorsky N, Studenski M, Dicker A, Gomella L, Den R . Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care?. Cancer Treat Rev. 2012; 39(3):212-8. DOI: 10.1016/j.ctrv.2012.10.003. View

18.

Madsen B, Hsi R, Pham H, Presser J, Esagui L, Corman J . Intrafractional stability of the prostate using a stereotactic radiotherapy technique. Int J Radiat Oncol Biol Phys. 2003; 57(5):1285-91. DOI: 10.1016/s0360-3016(03)00746-6. View

19.

Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley W, Sokol G . Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65(4):965-74. DOI: 10.1016/j.ijrobp.2006.04.029. View

20.

Yeoh E, Holloway R, Fraser R, Botten R, Di Matteo A, Butters J . Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006; 66(4):1072-83. DOI: 10.1016/j.ijrobp.2006.06.005. View